Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Chronic myelogenous leukemia

J E Cortes1, S O'Brien

  • 1University of Texas MD Anderson Cancer Center, Houston.

Current Opinion in Oncology
|January 1, 1994
PubMed
Summary
This summary is machine-generated.

Chronic myelogenous leukemia (CML) pathogenesis remains unclear, but new therapies like homoharringtonine chemotherapy and advanced bone marrow transplantation show promise. Sensitive molecular techniques aid in assessing treatment efficacy for CML patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia.

Leukemia·2020
Same author

Therapeutic targeting of membrane-associated GRP78 in leukemia and lymphoma: preclinical efficacy in vitro and formal toxicity study of BMTP-78 in rodents and primates.

The pharmacogenomics journal·2017
Same author

Clinical and prognostic significance of e1a2 BCR-ABL1 transcript subtype in chronic myeloid leukemia.

Blood cancer journal·2017
Same author

Donor type, in addition to transplantation in chronic phase and myeloablative conditioning, influence transplant survival for patients with advanced chronic myeloid leukemia in the era of tyrosine kinase inhibitors.

Leukemia·2017
Same author

Characteristics, outcomes, prognostic factors and treatment of patients with T-cell prolymphocytic leukemia (T-PLL).

Annals of oncology : official journal of the European Society for Medical Oncology·2017
Same author

Differential depth of treatment response required for optimal outcome in patients with blast phase versus chronic phase of chronic myeloid leukemia.

Blood cancer journal·2017
Same journal

Artificial intelligence-augmented robotic surgery in gynecologic oncology: intraoperative assistance and analytics.

Current opinion in oncology·2026
Same journal

Artificial intelligence in cervical cancer screening and triage: a role-stratified systematic review and bivariate meta-analysis.

Current opinion in oncology·2026
Same journal

Deep learning assisting the surgical management of gynecologic cancers.

Current opinion in oncology·2026
Same journal

Pain management in pancreatic cancer: time to change our strategy!

Current opinion in oncology·2026
Same journal

Systemic radionuclide treatments in gastro-entero-pancreatic neuroendocrine tumours.

Current opinion in oncology·2026
Same journal

5-Fluorouracil at seventy: still attractive but barely understood. A cautionary tale for drug development.

Current opinion in oncology·2026
See all related articles

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • The Philadelphia chromosome (Ph) is characteristic of chronic myelogenous leukemia (CML).
  • Molecular events driving CML pathogenesis and progression to advanced phases are not fully understood.
  • Treatment strategies for CML, including interferon therapy and bone marrow transplantation, have varying outcomes and ongoing research focus.

Purpose of the Study:

  • To explore the molecular basis of chronic myelogenous leukemia pathogenesis.
  • To review current and emerging therapeutic strategies for CML.
  • To highlight the role of sensitive molecular techniques in evaluating CML treatment outcomes.

Main Methods:

  • Review of existing literature on CML pathogenesis and treatment.

Related Experiment Videos

  • Discussion of novel therapeutic agents and transplantation modalities.
  • Emphasis on molecular diagnostic techniques for monitoring minimal residual disease.

    • Main Results:

    • The molecular mechanisms underlying CML progression to accelerated and blastic phases require further elucidation.
    • New therapies, including homoharringtonine chemotherapy and advancements in bone marrow transplantation (unrelated donors, autologous purging), offer improved outcomes.
    • Sensitive molecular assays can detect minimal residual disease, aiding in treatment response assessment.

    Conclusions:

    • Further research is needed to fully understand CML pathogenesis at the molecular level.
    • A range of novel therapeutic options are emerging for CML management.
    • Molecular monitoring is crucial for assessing the effectiveness of CML therapies and guiding future treatment decisions.